 Hologic Inc NASDAQ: HOLX reported Q2 FY22 sales of 1.44 billion, down 7 YY, and beating the consensus Wall Street estimate for revenues of 1.29 billion. Lower sales of COVID-19 assays primarily drove a fall in sales. 